Literature DB >> 15147575

Induction of immune responses against human papillomaviruses by hypervariable epitope constructs.

K Jyotsna Reddy1, Babak Banapour, David E Anderson, Sang H Lee, Juan P Marquez, Maria P Carlos, Jose V Torres.   

Abstract

An ideal prophylactic vaccine against human papillomaviruses (HPV) would be one that can induce broadly reactive antibody titres to at least the major oncogenic strains of HPV. It has been previously shown that HPV structural proteins are highly immunogenic but fail to elicit cross-reactive immune responses against heterologous strains of HPV. Recent studies have demonstrated that the immunity induced by virus-like particles is mostly type specific. In the present study, we determined the breadth of reactivity of antibodies induced in mice immunized with hypervariable epitope constructs (HECs), which represent sequence variants of immunodominant B-cell epitopes of the major capsid protein L1 of HPV. In order to test the breadth of reactivity, sera from immunized mice were tested against peptides representing analogous sequences of HPV types 16, 18, 31 and 45. Mice immunized with HECs based on two epitopes mounted antibody responses that cross-reacted with two different analogues, 16 and 18. Significantly, antibodies from mice immunized with HECs also inhibited haemagglutination mediated by HPV-16 L1 VLPs, suggesting that immunization resulted in the development of antibodies that could bind to viral capsid proteins in their native conformation. Our observations suggest that HECs may overcome the restriction of type specific immunity against HPV.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147575      PMCID: PMC1782473          DOI: 10.1111/j.1365-2567.2004.01873.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

1.  Immunogenicity of a vaccine preparation representing the variable regions of the HIV type 1 envelope glycoprotein.

Authors:  M P Carlos; D E Anderson; M B Gardner; J V Torres
Journal:  AIDS Res Hum Retroviruses       Date:  2000-01-20       Impact factor: 2.205

Review 2.  Strategies for HPV prevention.

Authors:  Martyn Plummer; Silvia Franceschi
Journal:  Virus Res       Date:  2002-11       Impact factor: 3.303

3.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

4.  The theoretical population-level impact of a prophylactic human papilloma virus vaccine.

Authors:  James P Hughes; Geoff P Garnett; Laura Koutsky
Journal:  Epidemiology       Date:  2002-11       Impact factor: 4.822

5.  Physical interaction of human papillomavirus virus-like particles with immune cells.

Authors:  D M Da Silva; M P Velders; J D Nieland; J T Schiller; B J Nickoloff; W M Kast
Journal:  Int Immunol       Date:  2001-05       Impact factor: 4.823

6.  Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles.

Authors:  T J Palker; J M Monteiro; M M Martin; C Kakareka; J F Smith; J C Cook; J G Joyce; K U Jansen
Journal:  Vaccine       Date:  2001-06-14       Impact factor: 3.641

7.  Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.

Authors:  C D Harro; Y Y Pang; R B Roden; A Hildesheim; Z Wang; M J Reynolds; T C Mast; R Robinson; B R Murphy; R A Karron; J Dillner; J T Schiller; D R Lowy
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

8.  Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes.

Authors:  C Leder; J A Kleinschmidt; C Wiethe; M Müller
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

9.  A controlled trial of a human papillomavirus type 16 vaccine.

Authors:  Laura A Koutsky; Kevin A Ault; Cosette M Wheeler; Darron R Brown; Eliav Barr; Frances B Alvarez; Lisa M Chiacchierini; Kathrin U Jansen
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

10.  Cost-effectiveness of a potential vaccine for human papillomavirus.

Authors:  Gillian D Sanders; Al V Taira
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more
  1 in total

1.  Characterization of a permissive epitope insertion site in adenovirus hexon.

Authors:  Michael J McConnell; Xavier Danthinne; Michael J Imperiale
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.